Cannabidiol in Neurology: Current Insights and Translational Perspectives
Pharmaceuticals · 17.02.2026 · 19 (2) · 330
DOI: 10.3390/ph19020330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 17.02.2026. Verfasst von Magdalena Białoń und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Cracow, Poland. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TrePsy project from the European Union's Horizon Europe, The National Science Centre, Poland, TrePsy project from the European Union’s Horizon Europe.
Abstract (Originalsprache)
Cannabidiol (CBD) is one of the most studied compounds of Cannabis sativa and has attracted significant interest due to its therapeutic and beneficial properties, which have been confirmed in numerous preclinical and clinical studies over the last few years. A great advantage of CBD over the other widely known Cannabis sativa ingredient, Δ-9-tetrahydrocannabinol (THC), is that CBD does not exert intoxicating and psychoactive effects, making it an attractive candidate for therapeutic applications in neurological disorders. CBD has been shown to exert antioxidant, analgesic, anti-inflammatory, and neuroprotective effects, with therapeutic potential for various neurological conditions. To date, the only drug that consists solely of highly purified CBD is Epidiolex, which is used in the management of severe forms of epilepsy such as Dravet syndrome and Lennox–Gastaut syndrome. Another legal medication containing CBD (albeit with the addition of THC) is Sativex, used to alleviate spasticity in multiple sclerosis. Besides epilepsy, preclinical data suggest that CBD alone may be potentially beneficial in treating chronic pain, multiple sclerosis, Alzheimer’s and Parkinson’s diseases, or stroke. The safety profile of CBD is generally considered favorable, as the most commonly reported adverse effects are mild (e.g., somnolence, diarrhea). However, much attention should be paid as CBD-driven drug–drug interactions have been reported. This review article aims to assess the outcomes of preclinical and clinical research on CBD’s effects in various neurological conditions while also addressing potential risks and concerns related to its use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurochemistry, Maj Institute of Pharmacology, Polish Academy of Sciences, 31-343 Cracow, Poland.
ORCID-Profile: Magdalena Białoń, Marta Kędziora, Katarzyna Starowicz
Förderung
- TrePsy project from the European Union's Horizon Europe
- The National Science Centre, Poland
- TrePsy project from the European Union’s Horizon Europe
Zitieren
APA
Białoń, M., Kędziora, M., & Starowicz, K. (2026). Cannabidiol in Neurology: Current Insights and Translational Perspectives. Pharmaceuticals, 19(2), 330. https://doi.org/10.3390/ph19020330
Vancouver
Białoń M, Kędziora M, Starowicz K. Cannabidiol in Neurology: Current Insights and Translational Perspectives. Pharmaceuticals. 2026;19(2):330. doi:10.3390/ph19020330
BibTeX
@article{Biao2026,
author = {Białoń, Magdalena and Kędziora, Marta and Starowicz, Katarzyna},
title = {Cannabidiol in Neurology: Current Insights and Translational Perspectives},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {2},
pages = {330},
doi = {10.3390/ph19020330}
}
EUVIMED